Oxford Cancer Biomarkers Licenses China Rights for Three Colorectal Cancer Tests

Oxford Cancer Biomarkers (OCB) said it will expand the use of three of its in vitro diagnostic tests for colorectal cancer into China through a partnership with My-BioMed Biotechnology (MBM).The value of the collaboration was not disclosed.MBM, a China-focused precision medicine company launched last year, has gained rights to OCB’s ColoTox, ColoProg, and ColoPredict tests, and will build a biomedical laboratory in Ningbo Meishan Free Trade Zone.The three tests are among four biomarker dia